Induction Therapy for Advanced-stage Hodgkin Lymphoma Late Intensification (ABVD Chemotherapy Followed by High-dose Chemotherapy and Autologous Stem Cell Transplant Only for Those Who Relapse)

被引：3

作者：

Ansell, Stephen M. ^{[1
]}

机构：

[1] Mayo Clin, Div Hematol, Rochester, MN 55905 USA

来源：

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2014年 / 28卷 / 01期

关键词：

Hodgkin lymphoma; ABVD chemotherapy; Escalated BEACOPP; Response rate; Toxicity; Failure-free survival (FFS); Event-free survival (EFS); Overall survival (OS); REED-STERNBERG CELLS; STUDY-GROUP GHSG; STANFORD V; RANDOMIZED-TRIAL; GONADAL-FUNCTION; BEACOPP; FERTILITY; TOXICITY; DISEASE; BLEOMYCIN;

D O I：

10.1016/j.hoc.2013.10.003

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The goal of therapy for patients with advanced-stage Hodgkin lymphoma is to ensure that as many patients as possible are healthy and free of disease decades after completing treatment. To achieve this, the treating physician needs to select the most effective therapeutic regimen, but also needs to choose a treatment strategy that limits long-term toxicity. One approach to achieve this is to use a less intense combination, such as ABVD chemotherapy, as initial treatment and intensify therapy only in those patients who do not become PET negative or who subsequently relapse.

引用

页码：75 / +

页数：14

共 34 条

[1]

[Anonymous], J CLIN ONCOLOGY S

[2] Hodgkin lymphoma: 2012 update on diagnosis, risk-stratification, and management [J].

Ansell, Stephen M. .

AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 (12) :1096-1103

[3] A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly) [J].

Ballova, V ;

Rüffer, JU ;

Haverkamp, H ;

Pfistner, B ;

Müller-Hermelink, HK ;

Dühmke, E ;

Worst, P ;

Wilhelmy, M ;

Naumann, R ;

Hentrich, M ;

Eich, HT ;

Josting, A ;

Löffler, M ;

Diehl, V ;

Engert, A .

ANNALS OF ONCOLOGY, 2005, 16 (01) :124-131

[4] No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group [J].

Behringer, K. ;

Wildt, L. ;

Mueller, H. ;

Mattle, V. ;

Ganitis, P. ;

van den Hoonaard, B. ;

Ott, H. W. ;

Hofer, S. ;

Pluetschow, A. ;

Diehl, V. ;

Engert, A. ;

Borchmann, P. .

ANNALS OF ONCOLOGY, 2010, 21 (10) :2052-2060

[5] Gonadal Function and Fertility in Survivors After Hodgkin Lymphoma Treatment Within the German Hodgkin Study Group HD13 to HD15 Trials [J].

Behringer, Karolin ;

Mueller, Horst ;

Goergen, Helen ;

Thielen, Indra ;

Eibl, Angelika Diana ;

Stumpf, Volker ;

Wessels, Carsten ;

Tz, Martin Wiehlpu ;

Rosenbrock, Johannes ;

Halbsguth, Teresa ;

Reiners, Katrin S. ;

Schober, Thomas ;

Renno, Jorg H. ;

von Wolff, Michael ;

van der Ven, Katrin ;

Kuehr, Marietta ;

Fuchs, Michael ;

Diehl, Volker ;

Engert, Andreas ;

Borchmann, Peter .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (02) :231-239

[6] Analysis of factors influencing inclusion of 102 patients with stage III/IV Hodgkin's lymphoma in a randomized trial for first-line chemotherapy [J].

Biasoli, I. ;

Franchi-Rezgui, P. ;

Sibon, D. ;

Briere, J. ;

de Kerviler, E. ;

Thieblemont, C. ;

Levy, V. ;

Gisselbrecht, C. ;

Brice, P. .

ANNALS OF ONCOLOGY, 2008, 19 (11) :1915-1920

[7] ABVD in Older Patients With Early-Stage Hodgkin Lymphoma Treated Within the German Hodgkin Study Group HD10 and HD11 Trials [J].

Boell, Boris ;

Goergen, Helen ;

Fuchs, Michael ;

Pluetschow, Annette ;

Eich, Hans Theodor ;

Bargetzi, Mario J. ;

Weidmann, Eckhart ;

Junghanss, Christian ;

Greil, Richard ;

Scherpe, Alexander ;

Schmalz, Oliver ;

Eichenauer, Dennis A. ;

von Tresckow, Bastian ;

Rothe, Achim ;

Diehl, Volker ;

Engert, Andreas ;

Borchmann, Peter .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (12) :1522-1529

[8] Eight Cycles of Escalated-Dose BEACOPP Compared With Four Cycles of Escalated-Dose BEACOPP Followed by Four Cycles of Baseline-Dose BEACOPP With or Without Radiotherapy in Patients With Advanced-Stage Hodgkin's Lymphoma: Final Analysis of the HD12 Trial of the German Hodgkin Study Group [J].

Borchmann, Peter ;

Haverkamp, Heinz ;

Diehl, Volker ;

Cerny, Thomas ;

Markova, Jana ;

Ho, Anthony D. ;

Eich, Hans-Theodor ;

Mueller-Hermelink, Hans Konrad ;

Kanz, Lothar ;

Greil, Richard ;

Rank, Andreas ;

Paulus, Ursula ;

Smardova, Lenka ;

Huber, Christoph ;

Doerken, Bernd ;

Nerl, Christoph ;

Krause, Stefan W. ;

Mueller, Rolf-Peter ;

Fuchs, Michael ;

Engert, Andreas .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (32) :4234-4242

[9] Long-Term Follow-Up Analysis of HD9601 Trial Comparing ABVD Versus Stanford V Versus MOPP/EBV/CAD in Patients With Newly Diagnosed Advanced-Stage Hodgkin's Lymphoma: A Study From the Intergruppo Italiano Linfomi [J].

Chisesi, Teodoro ;

Bellei, Monica ;

Luminari, Stefano ;

Montanini, Antonella ;

Marcheselli, Luigi ;

Levis, Alessandro ;

Gobbi, Paolo ;

Vitolo, Umberto ;

Stelitano, Caterina ;

Pavone, Vincenzo ;

Merli, Francesco ;

Liberati, Marina ;

Baldini, Luca ;

Bordonaro, Roberto ;

Pesce, Emanuela Anna ;

Federico, Massimo .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (32) :4227-4233

[10] Evaluation of acute and early cardiotoxicity in survivors of Hodgkin's disease treated with ABVD or BEACOPP regimens [J].

Elbl, L. ;

Vasova, I. ;

Kral, Z. ;

Tomaskova, I. ;

Smardova, L. ;

Wagnerova, B. ;

Jedlicka, F. ;

Vorlicek, J. .

JOURNAL OF CHEMOTHERAPY, 2006, 18 (02) :199-208

← 1 2 3 4 →